- Home
- Companies
- usa maryland
- cardiovascular
Show results for
Refine by
Cardiovascular Suppliers In Usa Maryland
4 companies found
based inParsippany, NEW JERSEY (USA)
At Zoetis, our purpose is to nurture our world and humankind by advancing care for animals. It’s an ambitious and humbling pursuit, but with a diverse and talented team supporting our customers all around the world, we’ve experienced 70 years of ...
Every day around the globe Alfaxan Multidose Intravenous Injectable Anesthetic is used in thousands of anesthetic procedures. Its effectiveness, wide safety profile and versatility is raising the bar for injectable agents used in induction and total ...
based inSilver Spring, MARYLAND (USA)
We develop, manufacture, and launch regenerative medicine solutions that help to support you and your goals. Aziyo Biologics has an extensive history and experience developing, manufacturing, and launching regenerative medicine products. No one ...
An extracellular matrix derived from porcine small intestine submucosa (SIS), ProxiCor for Cardiac Tissue Repair (CTR) regulates the biologic healing response to decrease inflammation and stimulate formation of healthy tissue.2,3 When sutured next ...
based inHouston, TEXAS (USA)
CUSABIO is a National High-Tech Enterprise with research, production and sales in one. After 16 years of effort, CUSABIO has become a good partner to researchers through worldwide. We are dedicated to providing 60,000+ validated antibodies, 10,000+ ...
Alias: N/A. Biological_Activity: Not test. Purity: >95% (SDS-PAGE). Sequence: Full length protein. Research Area: Cardiovascular. Source: Purified from Human heart tissue. Protein Names: Human Myoglobin protein. Storage: Aliquot ...
based inSilver Spring, MARYLAND (USA)
We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical ...
Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional ...